Importantly, recent works demonstrated that FLT3-ITD-independent activation of STAT5 induced by the leukemic microenvironment promotes resistance of FLT3-ITD+ AML cells to quizartinib, an FLT3 inhibitor that is now in phase 3 clinical trial [84]. Here, STAT5A is linked to acute myeloid leukemia.